Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b.
暂无分享，去创建一个
S. Aamdal | L. Bastholt | J. Hansson | Y. Brandberg | H. von der Maase | U. Stierner | M. Hernberg | U. Stierner | H. Maase | M. Hernberg | Jonny Hansson